GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump’s push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff relief, a major Swiss chemical and pharmaceutical industry association said on Wednesday. Pfizer and Trump said on Tuesday they had reached a deal in which the U.S. company would lower prescription drug prices in the federal Medicaid programme to match those it charges in other developed countries and offer similar pricing on all new drugs launched in the U.S. In July, Trump sent letters to 17 leading drug companies, including Swiss firms Novartis and Roche, instructing them to cut U.S. prices to match those paid overseas.
Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says
